Intest Res Search

CLOSE


Intest Res > Volume 0(); > Article
DOI: https://doi.org/10.5217/ir.2018.00084    Published online November 12, 2018.
WITHDRAWN:Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members
Soo-Kyung Park1, Tadakazu Hisamatsu2, Zhihua Ran3, Shu-Chen Wei4, Dong Il Park1
1Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
3Department of Gastroenterology, Shanghai Jiao Tong University, Shanghai, China
4Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
Correspondence:  Dong Il Park, Tel: +82-2-2001-2059, Fax: +82-2-2001-2049, 
Email: diksmc.park@samsung.com
Received: 12 June 2018   • Revised: 5 September 2018   • Accepted: 6 October 2018
Key Words: Biosimilar pharmaceuticals, Infliximab, Asia, Knowledge
TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 0 Crossref
  •   Scopus
  • 4,112 View
  • 43 Download
We recommend


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2019 by Korean Association for the Study of Intestinal Diseases. All rights reserved.

Developed in M2community

Close layer
prev next